Lexeo Therapeutics (LXEO) Institutional Ownership → This Could be Your “Big Money” AI Moment (From InvestorPlace) (Ad) Free LXEO Stock Alerts $13.77 -0.08 (-0.58%) (As of 04:17 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Lexeo Therapeutics (NASDAQ:LXEO)CurrentInstitutional OwnershipPercentage60.67%Number ofInstitutional Buyers(last 12 months)10TotalInstitutional Inflows(last 12 months)$98.52MNumber ofInstitutional Sellers(last 12 months)0 Get LXEO Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexeo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LXEO Institutional Buying and Selling by Quarter Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. Lexeo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/17/2024 RA Capital Management L.P.660,938$10.36M0.1%N/A2.006% 5/17/2024 Artal Group S.A.801,716$12.57M0.3%+32.9%2.434% 5/16/2024 Janus Henderson Group PLC2,540,785$39.80M0.0%+9.0%7.713% 5/14/2024 American International Group Inc.5,053$79K0.0%N/A0.015% 5/10/2024 Vanguard Group Inc.481,755$7.55M0.0%+15.8%1.462% 5/1/2024 BNP Paribas Financial Markets4,781$75K0.0%N/A0.015% 4/29/2024 Cornell University126,258$1.98M30.0%N/A0.383% 2/20/2024 Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268% 2/15/2024 Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096% 2/15/2024 Blackstone Inc.696,110$9.34M0.0%N/A2.612% (Data available from 1/1/2016 forward) LXEO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LXEO shares? During the previous two years, 10 institutional investors and hedge funds held shares of Lexeo Therapeutics. The most heavily invested institutionals were Eventide Asset Management LLC ($40.30M), Janus Henderson Group PLC ($39.80M), Omega Fund Management LLC ($28.96M), Artal Group S.A. ($12.57M), RA Capital Management L.P. ($10.36M), Blackstone Inc. ($9.34M), and Vanguard Group Inc. ($7.55M).Learn more on LXEO's institutional investors. What percentage of Lexeo Therapeutics stock is owned by institutional investors? 60.67% of Lexeo Therapeutics stock is owned by institutional investors. Learn more on LXEO's institutional investor holdings. Which institutional investors have been buying Lexeo Therapeutics stock? Of the 10 institutional investors that purchased Lexeo Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Eventide Asset Management LLC ($3.00M), Omega Fund Management LLC ($2.16M), Blackstone Inc. ($696.11K), RA Capital Management L.P. ($660.94K), Janus Henderson Group PLC ($210.05K), Artal Group S.A. ($198.28K), and Cornell University ($126.26K). How much institutional buying is happening at Lexeo Therapeutics? Institutional investors have bought a total of 7,127,495 shares in the last 24 months. This purchase volume represents approximately $98.52M in transactions. Related Companies: Editas Medicine Institutional Ownership Voyager Therapeutics Institutional Ownership Fate Therapeutics Institutional Ownership iTeos Therapeutics Institutional Ownership C4 Therapeutics Institutional Ownership Taysha Gene Therapies Institutional Ownership Ocugen Institutional Ownership Alvotech Institutional Ownership Allogene Therapeutics Institutional Ownership Replimune Group Institutional Ownership This page (NASDAQ:LXEO) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.